All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Justin Loke, University of Birmingham, Birmingham, UK. We asked, Is a TP53 mutation always a poor prognostic marker for transplantation in AML?
Is a TP53 mutation always a poor prognostic marker for transplantation in AML?
Historically, patients with TP53 mutations have been known to have adverse prognostic features even after intensive chemotherapy treatment, rendering the option of allogeneic transplantation of little value to the patient. In this video, Loke reviews transplant variables and other prognostic factors affecting the outcomes of patients with TP53-AML who have undergone allogeneic transplant.
Evaluating predictive factors for post-HSCT survival in secondary AML
Patients with secondary acute myeloid leukemia (sAML) have poor clinical outcomes, even after intensive chemotherapy, and allogeneic hematopoietic stem cell transplantation (HSCT)...
Patients with pretransplant MRD may benefit from conditioning intensification
At the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub will hold a satellite symposium on how measurable residual...
Subscribe to get the best content related to AML delivered to your inbox